Nettoomsättningen uppgick till 204,6 MSEK (199,3), vilket motsvarade en ökning med 2,7% y-o-y.
Redeye provides its initial take on Acarix’s Q1 report, which showed growth in both revenue and inst...
Telko and Leipurin segments both reported EUR 0.3m higher adjusted EBITA than we forecasted in Q1.
During the weekend, Sprint Bioscience announced that the US firm Day One has decided to discontinue ...
Group net sales was EUR 28.4m in Q1 (Nordea EUR 28.
Redeye provides a research update following the Q1 report recently published by Initiator Pharma.
Redeye provides a research update following Catella’s Q1 2025 report.
CapMan posted a solid set of Q1 numbers, with fee income growing 8% y/y, roughly in line with our ex...
Redeye provides a brief comment on the news that 85% of the TO 12 warrant program has been secured a...
- Investments in sales held back margins in Q1... - .
Ahead of Relais Q1, we maintain our estimates intact.
Redeye is optimistic about Alligator’s completion of GMP production of mitazalimab, a precondition f...
Redeye notes an exceptionally strong Q1 with record sales.
Balanced regional growth with broad-based support from the Medical Device segment.
Redeye updates on W5 Solutions following a softer than expected Q1-report.
